Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders
Servier Group announced a multi-target research collaboration with the n-Lorem Foundation, a non-profit research organization...
Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. announced it has published its prospectus and filed for listing...
Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix...
Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...
Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical...
Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...
Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Harbour BioMed (HKG: 2142) announced it will co-establish, together with U.S. biotechnology company BioMap, a...
BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China’s National Medical Products Administration (NMPA) has granted...
Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers
Lonza Group Ltd. (SWX: LONN) and Antharis Therapeutics announced on June 15, 2026, an exclusive,...
AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035
ZERO Prostate Cancer, the leading prostate cancer organization in the United States, announced on June...
Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution
Johnson & Johnson (J&J, NYSE: JNJ) announced a $1+ billion investment in Jacksonville, Florida, to...
Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders
Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing...
Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...
Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader
Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products...
TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals
TriApex Laboratories Co., Ltd. announced it has published its prospectus and formally applied for listing...
Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services
Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...
Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment
Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China’s National Medical Products...
Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center
Baheal Pharma Group (SHE: 301015) announced a strategic partnership with Jinan Junxin Cancer Hospital to...